Emergent BioSolutions posts Q2 revenue surge but takes $191 million impairment, cuts 2026 outlook
The company reported 66% revenue growth on government biodefense contracts while announcing a restructuring plan and slashing its full-year revenue forecast by up to $85 million.
Emergent BioSolutions reported second quarter 2026 results on August 5, 2026, showing total revenues of $234.3 million, an improvement of 66% versus prior year, alongside a net loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge1.
CEO Joe Papa said the quarter significantly exceeded the high end of guidance, primarily driven by accelerated MCM/biodefense contract modifications secured with the U.S. government1. He also said the company is "at a critical juncture in our turnaround and transformation, primarily stemming from our naloxone business"1.
The impairment stemmed from a non-cash impairment charge in the second quarter of 2026 related to the NARCAN® asset group within the Commercial reporting unit1. Naloxone revenue itself decreased $15.1 million, or 22%, as compared with Q2 20251, while Smallpox MCM revenue increased $61.0 million, or 150%, primarily attributable to higher USG sales of ACAM2000® due to timing, higher CNJ-016® sales, and higher TEMBEXA® international sales due to timing1.
The company disclosed a restructuring plan under Item 2.05 of the filing, stating it will reduce its current workforce by approximately 93 employees across all areas of the Company and eliminate approximately 21 vacant positions, as well as close wet laboratories in Gaithersburg, Maryland1. It expects annualized savings of approximately $40 million when fully implemented1, with approximately $10 million to $11.5 million in charges expected primarily in the second half of 20261.
In personnel changes, the Company will eliminate the role of Chief Medical Officer, Head of Research and Development, and Simon Lowry will leave the Company effective August 19, 20261, while Stephanie Duatschek was named Chief Growth Officer.
The company revised its full-year 2026 forecast, lowering total revenues to $645 million to $675 million from a previous range of $720 million to $760 million, and net loss to a range of $(245) million to $(225) million from $(30) million to $(10) million1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.